Table 1 shows susceptibility results for the Pseudomonas isolates to TTO and two of the five oil components tested. There was no difference in the susceptibility of the soil and clinical isolates. Both P. aeruginosa and P. fluorescens had MIC90 and MBC90 values of 4% for TTO. Similar values were obtained for a-ter- pineol. The MIC90 and MBC90 for terpinen-4-ol against P. aer- uginosa were both >8% while for P. fluorescens the values were 2% and >8%, respectively. P. putida isolates had lower MBCs for TTO (1%) and a-terpineol (2%), while the MBC90 for terpinen-4- ol was 4%. MIC and MBC values for g-terpinene, cineole and r- cymene were greater than 8% for all pseudomonads tested. As in previous studies,2 terpinen-4-ol and a-terpineol were the most active while cineole, g-terpinene and r-cymene were less so.
The antibiotic susceptibility profiles of the three species are shown in Table 2. All 56 isolates were susceptible to cefepime and all the P. fluorescens and P. putida isolates were susceptible to ciprofloxacin, gentamicin, meropenem and tobramycin.
P. aeruginosa and other Pseudomonas spp. are notorious for their involvement in nosocomial infections and their incidence of resistance to antibiotics. Adjunct or alternative treatments for Pseudomonas skin and wound infections that fall outside the realm of conventional antibiotics are needed. TTO is emerging as an alternative antimicrobial agent that is safe for topical appli- cations.9 A large number of products containing TTO as the active antimicrobial agent are available but there are limited in vitro data on the susceptibility of pseudomonads to TTO and no clinical data on the efficacy of these products in cutaneous infections involving Pseudomonas spp. Many TTO products intended for wound management or hand-washing contain 5–10% (w/v) TTO and, given that the MBC90 of TTO for P. aeruginosa was 4%, it is possible that the use of such topical agents in both the treatment of wounds and other skin washing situations may be of benefit in preventing and reducing infection and transmission. Whether TTO products can effectively treat cutaneous infections in which Pseudomonas spp. are involved remains to be determined in clinical studies. The possibility that Pseudomonas spp. may develop resistance to TTO also remains and requires clarification
Table 1 shows susceptibility results for the Pseudomonas isolates to TTO and two of the five oil components tested. There was no difference in the susceptibility of the soil and clinical isolates. Both P. aeruginosa and P. fluorescens had MIC90 and MBC90 values of 4% for TTO. Similar values were obtained for a-ter- pineol. The MIC90 and MBC90 for terpinen-4-ol against P. aer- uginosa were both >8% while for P. fluorescens the values were 2% and >8%, respectively. P. putida isolates had lower MBCs for TTO (1%) and a-terpineol (2%), while the MBC90 for terpinen-4- ol was 4%. MIC and MBC values for g-terpinene, cineole and r- cymene were greater than 8% for all pseudomonads tested. As in previous studies,2 terpinen-4-ol and a-terpineol were the most active while cineole, g-terpinene and r-cymene were less so.
The antibiotic susceptibility profiles of the three species are shown in Table 2. All 56 isolates were susceptible to cefepime and all the P. fluorescens and P. putida isolates were susceptible to ciprofloxacin, gentamicin, meropenem and tobramycin.
P. aeruginosa and other Pseudomonas spp. are notorious for their involvement in nosocomial infections and their incidence of resistance to antibiotics. Adjunct or alternative treatments for Pseudomonas skin and wound infections that fall outside the realm of conventional antibiotics are needed. TTO is emerging as an alternative antimicrobial agent that is safe for topical appli- cations.9 A large number of products containing TTO as the active antimicrobial agent are available but there are limited in vitro data on the susceptibility of pseudomonads to TTO and no clinical data on the efficacy of these products in cutaneous infections involving Pseudomonas spp. Many TTO products intended for wound management or hand-washing contain 5–10% (w/v) TTO and, given that the MBC90 of TTO for P. aeruginosa was 4%, it is possible that the use of such topical agents in both the treatment of wounds and other skin washing situations may be of benefit in preventing and reducing infection and transmission. Whether TTO products can effectively treat cutaneous infections in which Pseudomonas spp. are involved remains to be determined in clinical studies. The possibility that Pseudomonas spp. may develop resistance to TTO also remains and requires clarification
การแปล กรุณารอสักครู่..